funding from IMI2 and EFPIA
About ADAPT SMART
The ADAPT SMART* platform allows for all stakeholders to coordinate MAPP-related activities and to distribute key findings. It also aims to identify the scientific challenges and opportunities that might arise during the adoption of MAPPs. Outcomes from the consortium will inform future research agendas and provide a basis for discussing approaches to the implementation of MAPPs. Visit the ADAPT SMART website for more information.
*Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes.
Coordinating multi-stakeholder dialogue
The project reaches out to all stakeholders involved in the pathway of a medicine, from development to patient. Its international consortium brings together 32 partners, including the European Medicines Agency which fulfills the project leader role. Lygature coordinates the consortium, with roles and responsibilities that include:
- Program management. Lygature is responsible for overall program management, with the goal of supporting and monitoring effective execution of the work plan, including control of deliverables, milestones, and budgets.
- Coordination and leadership. Lygature is a co-lead in Work Package 2 of the project. This Work Package develops a roadmap for the MAPPs process for products, involving all phases of development and licensing as well as all relevant stakeholders (e.g. HTA, payers, clinical practice).
- Trusted partner. As an independent partner, Lygature safeguards different public and private interests from the proposal phase to the results phase, ensuring strict confidentiality.
ADAPT SMART is the first project under IMI to bring together, within a strategic policy, project stakeholders that include industry, regulatory authorities, patient organizations, physicians, health technology assessment institutions, and payers. It is a prime example of the Lygature mission to coordinate and combine complementary areas of expertise, and potentially different interests, in order to accelerate access to beneficial treatment options for appropriate patient groups.
Lygature together with
Abbvie, Amgen, Astellas, AstraZeneca, Bayer HealthCare, Boehringer-ingelheim, Bristol-Myers Squibb, Casmi, European Federation of Pharmaceutical Industries and Associations, European Medicines Agency, European Patients Forum, EURORDIS, GlaxoSmithKline, Haute Autorité de Santé, Ipsen, Janssen, Lilly, H. Lundbeck A/S, Lysogene, Merck KGaA, MIT NEWDIGS, MSD, NICE, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Sundheds Styrelsen, UCB, Zorginstituut Nederland
An interview with the ADAPT-SMART project coordinators
Today’s paradigms of bringing innovation to patients are challenged by new developments, such as a growing patient demand for timely access to promising therapies. To address this, more adaptive drug pathways are needed and the ADAPT-SMART project set out to address that challenge. In an interview with the IMI Programme office, project leader Hans-Georg Eichler of the European Medicines Agency (EMA), project coordinator Andre Broekmans of Lygature and deputy project leader Solange Rohou of AstraZeneca explained how the project created a change in the mindsets of players in the healthcare ecosystem, and how this will affect drug development in the future.
Concepts developed by ADAPT SMART published in Nature Reviews Drug Discovery
Earlier this month, Nature Reviews Drug Discovery (NRDD) published an article about Medicines Adaptive Pathways to Patients' (MAPPs). The NRDD article, co-authored by Lygature’s André Broekmans (Director Escher), describes the evolution of the adaptive approach and of concepts developed by ADAPT SMART.
ADAPT SMART Webinar on 19 April: "Putting Stakeholders at the Centre"
The first public webinar of ADAPT SMART will highlight how consortia members are collaborating with key stakeholder groups to incorporate their feedback into the project's deliverables during the calendar year of 2017.